Abstract

Myeloma patients not eligible for clinical trials have many treatment options. Choosing the next best therapy starts with careful assessment of the biology and dynamics of the disease at relapse, as well as the condition and situation of the patient. Fit patients should be considered for triplet regimens, whereas intermediate and frail patients warrant dose-reduced triplets or doublets. An indolent serologic relapse may be treated with dose intensification, especially in a maintenance situation, whereas a rapid relapse requires a more aggressive approach with drug class change or a second-generation immunomodulatory drug (IMID) or proteasome inhibitor (PI). Monoclonal antibodies, in combination with PIs and IMIDs, have proven highly efficacious in early and late relapse. Key elements of supportive care include infection prevention, bone health, thromboprophylaxis, and management of active symptoms, such as pain and distress.

References

References
1.
Unger
JM
,
Vaidya
R
,
Hershman
DL
,
Minasian
LM
,
Fleury
ME
.
Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation
.
J Natl Cancer Inst
.
2019
;
111
(
3
):
245
-
255
.
2.
Kim
ES
,
Bruinooge
SS
,
Roberts
S
, et al
.
Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement
.
J Clin Oncol
.
2017
;
35
(
33
):
3737
-
3744
.
3.
Lahuerta
JJ
,
Jiménez-Ubieto
A
,
Paiva
B
, et al
.
Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease
.
Blood
.
2019
;
133
(
25
):
2664
-
2668
.
4.
Wildes
TM
,
Anderson
KC
.
Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist
.
Hematology (Am Soc Hematol Educ Program)
.
2018
;
2018
:
88
-
96
.
5.
Palumbo
A
,
Bringhen
S
,
Mateos
MV
, et al
.
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
.
Blood
.
2015
;
125
(
13
):
2068
-
2074
.
6.
Moreau
P
,
Pylypenko
H
,
Grosicki
S
, et al
.
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
.
Lancet Oncol
.
2011
;
12
(
5
):
431
-
440
.
7.
Richardson
PG
,
Sonneveld
P
,
Schuster
MW
, et al
;
Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators
.
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
.
N Engl J Med
.
2005
;
352
(
24
):
2487
-
2498
.
8.
Rajkumar
SV
,
Blood
E
,
Vesole
D
,
Fonseca
R
,
Greipp
PR
;
Eastern Cooperative Oncology Group
.
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group
.
J Clin Oncol
.
2006
;
24
(
3
):
431
-
436
.
9.
Facon
T
,
Mary
JY
,
Hulin
C
, et al
;
Intergroupe Francophone du Myélome
.
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
.
Lancet
.
2007
;
370
(
9594
):
1209
-
1218
.
10.
Delforge
M
,
Ludwig
H
.
How I manage the toxicities of myeloma drugs
.
Blood
.
2017
;
129
(
17
):
2359
-
2367
.
11.
Walker
GV
,
Grant
SR
,
Guadagnolo
BA
, et al
.
Disparities in stage at diagnosis, treatment, and survival in nonelderly adult patients with cancer according to insurance status
.
J Clin Oncol
.
2014
;
32
(
28
):
3118
-
3125
.
12.
Olszewski
AJ
,
Dusetzina
SB
,
Eaton
CB
,
Davidoff
AJ
,
Trivedi
AN
.
Subsidies for oral chemotherapy and use of immunomodulatory drugs among Medicare beneficiaries with myeloma
.
J Clin Oncol
.
2017
;
35
(
29
):
3306
-
3314
.
13.
Doshi
JA
,
Li
P
,
Huo
H
,
Pettit
AR
,
Armstrong
KA
.
Association of patient out-of-pocket costs with prescription abandonment and delay in fills of novel oral anticancer agents
.
J Clin Oncol
.
2018
;
36
(
5
):
476
-
482
.
14.
Sonneveld
P
,
Avet-Loiseau
H
,
Lonial
S
, et al
.
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
.
Blood
.
2016
;
127
(
24
):
2955
-
2962
.
15.
Walker
BA
,
Mavrommatis
K
,
Wardell
CP
, et al
.
A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis
.
Leukemia
.
2019
;
33
(
1
):
159
-
170
.
16.
Fernández de Larrea
C
,
Kyle
RA
,
Durie
BG
, et al
;
International Myeloma Working Group
.
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
.
Leukemia
.
2013
;
27
(
4
):
780
-
791
.
17.
Touzeau
C
,
Moreau
P
.
How I treat extramedullary myeloma
.
Blood
.
2016
;
127
(
8
):
971
-
976
.
18.
Lonial
S
,
Weiss
BM
,
Usmani
SZ
, et al
.
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
.
Lancet
.
2016
;
387
(
10027
):
1551
-
1560
.
19.
Madan
S
,
Dispenzieri
A
,
Lacy
MQ
, et al
.
Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma
.
Mayo Clin Proc
.
2010
;
85
(
3
):
232
-
238
.
20.
Kourelis
TV
,
Kumar
SK
,
Gertz
MA
, et al
.
Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis
.
J Clin Oncol
.
2013
;
31
(
34
):
4319
-
4324
.
21.
Dispenzieri
A
,
Dingli
D
,
Kumar
SK
, et al
.
Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs
.
Am J Hematol
.
2010
;
85
(
10
):
757
-
759
.
22.
Bhutani
D
,
Leng
S
,
Eisenberger
A
, et al
.
Improvement in global longitudinal strain (GLS) correlates with NT-Probnp response in patients with cardiac amyloidosis treated on a Phase 1b study of anti-amyloid Mab Cael-101
.
Blood
.
2018
;
132
(
suppl 1
):
958
.
23.
Wechalekar
AD
,
Whelan
C
.
Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis
.
Blood Cancer J
.
2017
;
7
(
3
):
e546
.
24.
Rajkumar
SV
,
Harousseau
JL
,
Durie
B
, et al
;
International Myeloma Workshop Consensus Panel 1
.
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
.
Blood
.
2011
;
117
(
18
):
4691
-
4695
.
25.
Attal
M
,
Lauwers-Cances
V
,
Hulin
C
, et al
;
IFM 2009 Study
.
Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma
.
N Engl J Med
.
2017
;
376
(
14
):
1311
-
1320
.
26.
Moreau
P
,
Masszi
T
,
Grzasko
N
, et al
;
TOURMALINE-MM1 Study Group
.
Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma
.
N Engl J Med
.
2016
;
374
(
17
):
1621
-
1634
.
27.
Mateos
MV
,
Masszi
T
,
Grzasko
N
, et al
.
Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1
.
Haematologica
.
2017
;
102
(
10
):
1767
-
1775
.
28.
Kumar
SK
,
LaPlant
BR
,
Reeder
CB
, et al
.
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib
.
Blood
.
2016
;
128
(
20
):
2415
-
2422
.
29.
Dimopoulos
MA
,
Moreau
P
,
Palumbo
A
, et al
;
ENDEAVOR Investigators
.
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
.
Lancet Oncol
.
2016
;
17
(
1
):
27
-
38
.
30.
Dimopoulos
MA
,
Goldschmidt
H
,
Niesvizky
R
, et al
.
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
.
Lancet Oncol
.
2017
;
18
(
10
):
1327
-
1337
.
31.
Stewart
AK
,
Rajkumar
SV
,
Dimopoulos
MA
, et al
;
ASPIRE Investigators
.
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma
.
N Engl J Med
.
2015
;
372
(
2
):
142
-
152
.
32.
Siegel
DS
,
Dimopoulos
MA
,
Ludwig
H
, et al
.
Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma
.
J Clin Oncol
.
2018
;
36
(
8
):
728
-
734
.
33.
Spencer
A
,
Lentzsch
S
,
Weisel
K
, et al
.
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
.
Haematologica
.
2018
;
103
(
12
):
2079
-
2087
.
34.
Jakubowiak
A
,
Offidani
M
,
Pégourie
B
, et al
.
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
.
Blood
.
2016
;
127
(
23
):
2833
-
2840
.
35.
Paludo
J
,
Mikhael
JR
,
LaPlant
BR
, et al
.
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
.
Blood
.
2017
;
130
(
10
):
1198
-
1204
.
36.
Reece
DE
,
Trieu
Y
,
Masih-Khan
E
, et al
.
Cyclophosphamide and bortezomib with prednisone or dexamethasone for the treatment of relapsed and refractory multiple myeloma
.
Clin Lymphoma Myeloma Leuk
.
2016
;
16
(
7
):
387
-
394
.
37.
Offidani
M
,
Corvatta
L
,
Maracci
L
, et al
.
Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
.
Blood Cancer J
.
2013
;
3
(
11
):
e162
.
38.
Lentzsch
S
,
O’Sullivan
A
,
Kennedy
RC
, et al
.
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
.
Blood
.
2012
;
119
(
20
):
4608
-
4613
.
39.
Richardson
PG
,
Xie
W
,
Jagannath
S
, et al
.
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
.
Blood
.
2014
;
123
(
10
):
1461
-
1469
.
40.
Wang
M
,
Martin
T
,
Bensinger
W
, et al
.
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma
.
Blood
.
2013
;
122
(
18
):
3122
-
3128
.
41.
Dimopoulos
MA
,
San-Miguel
J
,
Belch
A
, et al
.
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
.
Haematologica
.
2018
;
103
(
12
):
2088
-
2096
.
42.
Lonial
S
,
Dimopoulos
M
,
Palumbo
A
, et al
;
ELOQUENT-2 Investigators
.
Elotuzumab therapy for relapsed or refractory multiple myeloma
.
N Engl J Med
.
2015
;
373
(
7
):
621
-
631
.
43.
Dimopoulos
MA
,
Lonial
S
,
Betts
KA
, et al
.
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial
.
Cancer
.
2018
;
124
(
20
):
4032
-
4043
.
44.
Papadopoulos
KP
,
Siegel
DS
,
Vesole
DH
, et al
.
Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma
.
J Clin Oncol
.
2015
;
33
(
7
):
732
-
739
.
45.
Berenson
JR
,
Cartmell
A
,
Bessudo
A
, et al
.
CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma
.
Blood
.
2016
;
127
(
26
):
3360
-
3368
.
46.
Durie
BG
,
Miguel
JF
,
Blade
J
,
Rajkumar
SV
.
Clarification of the definition of complete response in multiple myeloma
.
Leukemia
.
2015
;
29
(
12
):
2416
-
2417
.
47.
Kumar
SK
,
Dimopoulos
MA
,
Kastritis
E
, et al
.
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
.
Leukemia
.
2017
;
31
(
11
):
2443
-
2448
.
48.
Chari
A
,
Suvannasankha
A
,
Fay
JW
, et al
.
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
.
Blood
.
2017
;
130
(
8
):
974
-
981
.
49.
Chari
A
,
Martinez-Lopez
J
,
Mateos
MV
, et al
.
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
.
Blood
.
2019
;
134
(
5
):
421
-
431
.
50.
Lokhorst
HM
,
Plesner
T
,
Laubach
JP
, et al
.
Targeting CD38 with daratumumab monotherapy in multiple myeloma
.
N Engl J Med
.
2015
;
373
(
13
):
1207
-
1219
.
51.
Dimopoulos
MA
,
Dytfeld
D
,
Grosicki
S
, et al
.
Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma
.
N Engl J Med
.
2018
;
379
(
19
):
1811
-
1822
.
52.
Moreau
P
,
Mateos
M-V
,
Berenson
JR
, et al
.
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study
.
Lancet Oncol
.
2018
;
19
(
7
):
953
-
964
.
53.
Shah
JJ
,
Stadtmauer
EA
,
Abonour
R
, et al
.
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
.
Blood
.
2015
;
126
(
20
):
2284
-
2290
.
54.
Bringhen
S
,
Mina
R
,
Cafro
AM
, et al
.
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study
.
Leukemia
.
2018
;
32
(
8
):
1803
-
1807
.
55.
Krishnan
A
,
Kapoor
P
,
Palmer
JM
, et al
.
Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma
.
Leukemia
.
2018
;
32
(
7
):
1567
-
1574
.
56.
Miguel
JS
,
Weisel
K
,
Moreau
P
, et al
.
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
.
Lancet Oncol
.
2013
;
14
(
11
):
1055
-
1066
.
57.
Dimopoulos
MA
,
Palumbo
A
,
Corradini
P
, et al
.
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma
.
Blood
.
2016
;
128
(
4
):
497
-
503
.
58.
Nijhof
IS
,
Franssen
LE
,
Levin
MD
, et al
.
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma
.
Blood
.
2016
;
128
(
19
):
2297
-
2306
.
59.
Baz
RC
,
Martin
TG
III
,
Lin
HY
, et al
.
Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma
.
Blood
.
2016
;
127
(
21
):
2561
-
2568
.
60.
San-Miguel
JF
,
Hungria
VT
,
Yoon
SS
, et al
.
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
.
Lancet Oncol
.
2014
;
15
(
11
):
1195
-
1206
.
61.
Richardson
PG
,
Schlossman
RL
,
Alsina
M
, et al
.
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
.
Blood
.
2013
;
122
(
14
):
2331
-
2337
.
62.
Berdeja
JG
,
Hart
LL
,
Mace
JR
, et al
.
Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
.
Haematologica
.
2015
;
100
(
5
):
670
-
676
.
63.
Chari
A
,
Cho
HJ
,
Dhadwal
A
, et al
.
A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma
.
Blood Adv
.
2017
;
1
(
19
):
1575
-
1583
.
64.
Keats
JJ
,
Chesi
M
,
Egan
JB
, et al
.
Clonal competition with alternating dominance in multiple myeloma
.
Blood
.
2012
;
120
(
5
):
1067
-
1076
.
65.
Nooka
AK
,
Joseph
N
,
Boise
LH
,
Gleason
C
,
Kaufman
JL
,
Lonial
S
.
Clinical efficacy of daratumumab, pomalidomide and dexamethasone in relapsed, refractory myeloma patients: utility of retreatment with daratumumab among refractory patients
.
Blood
.
2016
;
128
(
22
):
492
.
66.
Giralt
S
,
Garderet
L
,
Durie
B
, et al
.
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
.
Biol Blood Marrow Transplant
.
2015
;
21
(
12
):
2039
-
2051
.
67.
Hagen
PA
,
Stiff
P
.
The role of salvage second autologous hematopoietic cell transplantation in relapsed multiple myeloma
.
Biol Blood Marrow Transplant
.
2019
;
25
(
3
):
e98
-
e107
.
68.
Griffin
PT
,
Ho
VQ
,
Fulp
W
, et al
.
A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma
.
Cancer
.
2015
;
121
(
20
):
3622
-
3630
.
69.
García-Sanz
R
,
Oriol
A
,
Moreno
MJ
, et al
;
Spanish Myeloma Group (GEM/PETHEMA)
.
Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial
.
Haematologica
.
2015
;
100
(
9
):
1207
-
1213
.
70.
Himelstein
AL
,
Foster
JC
,
Khatcheressian
JL
, et al
.
Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial
.
JAMA
.
2017
;
317
(
1
):
48
-
58
.
71.
Leng
S
,
Lentzsch
S
.
Bone-modifying agents: complicated to use
.
J Oncol Pract
.
2018
;
14
(
8
):
469
-
470
.
72.
Drayson
MT
,
Bowcock
S
,
Planche
T
, et al
.
Tackling Early Morbidity and Mortality in Myeloma (TEAMM): assessing the benefit of antibiotic prophylaxis and its effect on healthcare associated infections in 977 patients
.
Blood
.
2017
;
130
(
suppl 1
):
903
.
73.
Tomblyn
M
,
Chiller
T
,
Einsele
H
, et al
;
Centers for Disease Control and Prevention
.
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective [published correction appears in Biol Blood Marrow Transplant. 2010;16(2):294]
Biol Blood Marrow Transplant
.
2009
;
15
(
10
):
1143
-
1238
.
74.
National Comprehensive Cancer Network
.
Clinical Practice Guidelines in Oncology: Multiple Myeloma. www.nccn.org. Accessed 26 April 2019
.
75.
Davies
FE
.
Is molecular remission the goal of multiple myeloma therapy?
Hematology (Am Soc Hematol Educ Program)
.
2017
;
2017
:
205
-
211
.
76.
Avet-Loiseau
H
,
San-Miguel
JF
,
Casneuf
T
, et al
.
Evaluation of sustained minimal residual disease (MRD) negativity in relapsed/refractory multiple myeloma (RRMM) patients (Pts) treated with daratumumab in combination with lenalidomide plus dexamethasone (D-Rd) or bortezomib plus dexamethasone (D-Vd): analysis of Pollux and Castor
.
Blood
.
2018
;
132
(
suppl 1
):
3272
.
77.
Bahlis
NJ
,
Sutherland
H
,
White
D
, et al
.
Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
.
Blood
.
2018
;
132
(
24
):
2546
-
2554
.
78.
Vogl
DT
,
Dingli
D
,
Cornell
RF
, et al
.
Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma
.
J Clin Oncol
.
2018
;
36
(
9
):
859
-
866
.
79.
Moreau
P
,
Chanan-Khan
A
,
Roberts
AW
, et al
.
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
.
Blood
.
2017
;
130
(
22
):
2392
-
2400
.
80.
Larocca
A
,
Palumbo
A
.
Optimizing treatment for elderly patients with newly diagnosed multiple myeloma: a personalized approach
.
J Clin Oncol
.
2016
;
34
(
30
):
3600
-
3604
.
81.
Larocca
A
,
Dold
SM
,
Zweegman
S
, et al
.
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)
.
Leukemia
.
2018
;
32
(
8
):
1697
-
1712
.
82.
Jurczyszyn
A
,
Grzasko
N
,
Gozzetti
A
, et al
.
Central nervous system involvement by multiple myeloma: a multi-institutional retrospective study of 172 patients in daily clinical practice
.
Am J Hematol
.
2016
;
91
(
6
):
575
-
580
.
You do not currently have access to this content.